ERBB2 and breast cancer: In addition, only breast cancer patients who had triple-negative/basal-like subtypes were more likely to experience grade ≥ 3 neutropenia (OR = 2.53; 95% CI: 1.22–5.24) compared to patients with HR+/HER2-negative subtype (Table S3).